SC Asks Uttarakhand Govt To Finalize Decision On Suspension Of 14 Patanjali Products In Two Weeks

New Delhi: The Supreme Court on Tuesday directed the Uttarakhand government to decide on the suspension of 14 products by yoga guru Ramdev’s Patanjali Ayurved, reported Live Law.

A bench of Justices Hima Kohli and Sandeep Mehta directed the Bharatiya Janata Party government in the state to decide on the matter within two weeks.

On April 29, the Uttarakhand State Licensing Authority for Ayurvedic and Unani Services told the court that the licences were suspended as Patanjali Ayurved had repeatedly violated the 1945 Drugs and Cosmetic Rules.

The 14 drugs that had been suspended were: Swasari Gold, Swasari Vati, Bronchom, Swasari Pravahi, Swasari Avaleh, Mukta Vati Extra Power, Lipidom, Bp Grit, Madhugrit, Madhunashini Vati Extra Power, Livamrit Advance, Livogrit, Eyegrit Gold and Patanjali Drishti Eye Drop.

At the previous hearing on July 9, Patanjali Ayurved told a bench of Justices Hima Kohli and Sandeep Mehta that it had instructed 5,606 franchise stores to withdraw these products.

Media platforms were also instructed to withdraw advertisements for the 14 products, said the company. The court had asked Patanjali Ayurved to file an affidavit within two weeks, stating if social media intermediaries had withdrawn advertisements for the products.

At Tuesday’s hearing, the Indian Medical Association told the court that the 14 products were still available over the counter, even though Patanjali had earlier reportedly stopped their manufacturing.

Patanjali then told the court that the state government cancelled the suspension order on July 1 after considering the report of a committee constituted to look into the matter, reported Live Law.

Related Posts

KGMU prof suspended for forcing patients to buy meds from pvt store

Lucknow: Faculty member in the ophthalmology department of KGMU, Prof Sanjiv Gupta, was suspended on charges of prescribing medicines and lenses for cataract surgery that were available at a private…

CDSCO receives 1,387 adverse drug reaction reports in nine months of 2025

New Delhi: The pharmacovigilance division of the Central drug regulator has received a total of 1,387 adverse reports, with the highest regarding fixed dose combinations (FDCs), and a total of…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

KGMU prof suspended for forcing patients to buy meds from pvt store

KGMU prof suspended for forcing patients to buy meds from pvt store

World Record in Robotic Tele-Surgery takes Intercontinental Leap of 20,000 Km

World Record in Robotic Tele-Surgery takes Intercontinental Leap of 20,000 Km

CDSCO receives 1,387 adverse drug reaction reports in nine months of 2025

CDSCO receives 1,387 adverse drug reaction reports in nine months of 2025

NGT issues notice to Himachal pharma unit over pollution, water diversion allegations

NGT issues notice to Himachal pharma unit over pollution, water diversion allegations

Zydus Semaglutide approval: Delhi HC directs CDSCO to decide on patient safety concerns

Zydus Semaglutide approval: Delhi HC directs CDSCO to decide on patient safety concerns

DGFT Fixes Six New Standard Input Output Norms (SIONs) for Pharmaceutical and Chemical Exports

DGFT Fixes Six New Standard Input Output Norms (SIONs) for Pharmaceutical and Chemical Exports